Sandoz Group AG (SDZNY)
35.20
-0.79
(-2.20%)
USD |
OTCM |
May 20, 16:16
Sandoz Group Net Income (TTM): 353.45M for March 31, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 353.45M |
| December 31, 2023 | 185.28M |
| September 30, 2023 | 65.42M |
| June 30, 2023 | -260.14M |
| March 31, 2023 | -273.04M |
| Date | Value |
|---|---|
| December 31, 2022 | -321.80M |
| September 30, 2022 | -319.63M |
| June 30, 2022 | -209.18M |
| March 31, 2022 | -310.36M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-321.80M
Minimum
Dec 2022
353.45M
Maximum
Mar 2024
-121.11M
Average
-260.14M
Median
Jun 2023
Net Income (TTM) Benchmarks
| Novartis AG | 15.24B |
| AC Immune SA | -61.67M |
| CRISPR Therapeutics AG | -217.14M |
| Addex Therapeutics Ltd | -11.76M |
| NLS Pharmaceutics Ltd | -12.17M |